The win ratio: Impact of censoring and follow‐up time and use with nonproportional hazards-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The win ratio: Impact of censoring and follow‐up time and use with nonproportional hazards

Published:2019-10-31 Issue:3 Volume:19 Page:168-177
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Dong Gaohong¹^ORCID,Huang Bo²^ORCID,Chang Yu‐Wei³,Seifu Yodit⁴,Song James⁵,Hoaglin David C.⁶^ORCID

Affiliation:

1. iStats Inc. Long Island City NY USA

2. Pfizer Inc. Groton CT USA

3. BeiGene, Ltd. San Mateo CA USA

4. Merck & Co., Inc. Kenilworth NJ USA

5. BeiGene, Ltd. Ridgefield Park NJ USA

6. Department of Population and Quantitative Health SciencesUniversity of Massachusetts Medical School Worcester MA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.1977

Reference25 articles.

1. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

2. Generalized pairwise comparisons of prioritized outcomes in the two-sample problem

3. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials

4. An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring

5. An alternative approach to confidence interval estimation for the win ratio statistic

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On the intransitivity of the win ratio;Statistics & Probability Letters;2025-01

2. Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension;European Respiratory Journal;2024-08-29

3. Defining estimand for the win ratio: Separate the true effect from censoring;Clinical Trials;2024-07-30

4. Trial Design with Win Statistics for Multiple Time-to-Event Endpoints with Hierarchy;Statistics in Biopharmaceutical Research;2024-07-15

5. Rethinking Composite Endpoints With the Win Ratio: A Breakthrough or Business as Usual?;Canadian Journal of Cardiology;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3